Nuwellis Inc vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Nuwellis Inc trades at $1.4 (market cap $542.80K), while Vanguard Emerging Markets Stock Index Fund ETF trades at $60.4. The key difference: Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| NUWE | VWO | |
|---|---|---|
Market Cap | $542.80K | — |
Sector | Technology | — |
52-Week High | $220.50 | $61.24 |
52-Week Low | $1.42 | $51.20 |
Enterprise Value | -$1.27M | — |
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $1.41, down 0.7% today, with a bearish technical signal despite oversold RSI readings. The company reported a net loss of $17.52 million on $8.27 million revenue in 2025, with negative cash flow from operations. Recent news highlights expansion in pediatric care and a $3.4 million direct offering in July 2026, alongside a reverse stock split executed in June 2026.
Outlook remains challenged by persistent losses and high cash burn, though revenue growth and product development offer potential. Risks include reliance on financing and competitive pressures. Analyst consensus is split evenly between Buy and Hold, reflecting cautious optimism amid fundamental weaknesses.
VWO, the Vanguard FTSE Emerging Markets ETF, trades at $60.41, up 0.13% on the day, with a bullish technical signal from moving averages and a neutral reading from oscillators. The fund's low expense ratio of 0.06% and focus on emerging markets attract institutional inflows, as seen in recent 13F filings. Recent news highlights strong capital flows into emerging market ETFs and comparisons with peers on cost and diversification.
The outlook for VWO is supported by record inflows and favorable expense ratios, but risks include concentrated exposure to developing economies and currency volatility. Analyst sentiment is generally positive due to diversification benefits and cost efficiency, though geopolitical and economic uncertainties in emerging markets pose significant headwinds for sustained growth.
Trailing returns across standard periods
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →